Assessment of Rituximab's Immunomodulatory Synovial Effects (The ARISE Study)

• Status: Completed
• Trial end date: 2009-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Using repeated arthroscopic biopsies of patients with rheumatoid arthritis, the researchers will assess changes in the immune response that occur as a result of treatment with rituximab.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, San Diego
• Collaborator: Genentech, Inc.
• Treatments: Rituximab

Criteria

Inclusion Criteria:

• Active rheumatoid arthritis

• Use of concomitant methotrexate

Exclusion Criteria:

• Use of disease-modifying anti-rheumatic drugs (DMARDs)/biologics other than methotrexate

• Serious medical conditions that would preclude the use of the treating agent